effect of N-Acetyl cysteine on hsCRP level in patients with Peritoneal Dialysis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014063017380N2

Enrollment

Registered

2014-07-12

Start date

2013-02-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease. Chronic kidney disease, stage 5

Interventions

effervescent tablets acetylcysteine (NAC) two times a day orally for 8 weeks..

Treatment - Drugs

effervescent tablets acetylcysteine (NAC) two times a day orally for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: including criteria: all patients with Chronic Kidney Disease over 18 years old under Peritoneal Dialysis excluding criteria: patients under18 years old? history of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Hepatitis c and B and CRP over 50mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
High-sensitivity c reactive protein. Timepoint: before and after intervention. Method of measurement: by complete blood count test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzane Najafi

Shahid Sadoughi Univercity of Medical Sciences

drfnajafi@ssu.ac.ir+98 35 1822 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026